It may have been a nerve-shattering, sickeningly volatile ride. This downgrade was purely technical. I remain a believer in XOMA's management and pipeline and would recommend holding on to your shares for further long-term gains. DBOT is about to launch several clinical trials for human biotech products. Lysis DBOT's peptides destroy pathogens such as bacteria through a mechanism of action called lysis.
Lysis is the process of disrupting the wall of a cell.
When you punch enough holes in a cell wall, the cell dies. Lytic peptides work by punching holes in the walls of pathogenic cells. The first lytic peptides were isolated from the natural immune systems of humans, silkworms, frogs, and other animals. While the initial focus of lytic peptide research was pathogen destruction, it has become evident that certain lytic peptides have multiple mechanisms of action against diseases. Some of the same peptides that can kill bacteria appear to have possible anti-angiogenic activity, the Holy Grail of cancer research.